Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1998-12-7
pubmed:abstractText
MRL-lpr/lpr mice have a Fas receptor mutation that leads to abnormalities of apoptosis, lymphoproliferation, and a lupus-like autoimmune disease associated with the production of autoantibodies. Other than Fas pathway defects, little is known about molecular abnormalities that predispose to autoimmunity. Protein kinase CK2 (also termed casein kinase II), a serine-threonine protein kinase whose targets include many critical regulators of cellular growth, is highly expressed in a lymphoproliferative disease of cattle and in many human cancers. Overexpression of the CK2alpha catalytic subunit in lymphocytes of transgenic mice leads to T cell lymphoma. We hypothesized that CK2 dysregulation and Fas mutation might cooperatively augment lymphocyte proliferation and transformation. We find that in MRL-lpr/lpr mice bearing the CK2alpha transgene, the lymphoproliferative process is dramatically exacerbated, as these mice develop massive splenomegaly and lymphadenopathy by 12 wk of age in association with increased autoantibody production and accelerated renal disease. The lymphoid organs are filled with the unusual B220+CD4-CD8- T cells typically seen in MRL-lpr/lpr mice, not the B220-CD4+CD8+ or B220-CD4-CD8+ T cells typically seen in CK2a transgenic lymphomas. The T cells do not fulfill the criteria for transformation, as they are polyclonal and not transplantable or immortal in cell culture. Thus, although the lpr lymphoproliferative and autoimmune syndrome is potentiated by the presence of the CK2a transgene, this combination of apoptotic and proliferative abnormalities appears to be insufficient to transform lymphoid cells.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
161
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5164-70
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:9820486-Animals, pubmed-meshheading:9820486-Antigens, CD4, pubmed-meshheading:9820486-Antigens, CD45, pubmed-meshheading:9820486-Antigens, CD8, pubmed-meshheading:9820486-Autoimmune Diseases, pubmed-meshheading:9820486-Casein Kinase II, pubmed-meshheading:9820486-Gene Expression Regulation, pubmed-meshheading:9820486-Heterozygote, pubmed-meshheading:9820486-Homozygote, pubmed-meshheading:9820486-Lymphatic Diseases, pubmed-meshheading:9820486-Lymphoproliferative Disorders, pubmed-meshheading:9820486-Mice, pubmed-meshheading:9820486-Mice, Inbred MRL lpr, pubmed-meshheading:9820486-Mice, Knockout, pubmed-meshheading:9820486-Mice, Transgenic, pubmed-meshheading:9820486-Protein-Serine-Threonine Kinases, pubmed-meshheading:9820486-Splenomegaly, pubmed-meshheading:9820486-T-Lymphocyte Subsets, pubmed-meshheading:9820486-Transgenes
pubmed:year
1998
pubmed:articleTitle
Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha.
pubmed:affiliation
Department of Medicine, Boston University Medical Center, MA 02118, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't